Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorMADDEN, I.
dc.contributor.authorROUMENINA, L. T.
dc.contributor.authorLANGLOIS-MEURINNE, H.
dc.contributor.authorGUICHOUX, J.
dc.contributor.authorLLANAS, B.
dc.contributor.authorFREMEAUX-BACCHI, V.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
IDREF: 110567358
dc.contributor.authorGODRON-DUBRASQUET, A.
dc.date.accessioned2020-06-29T07:52:38Z
dc.date.available2020-06-29T07:52:38Z
dc.date.issued2019-03
dc.identifier.issn1432-198X (Electronic) 0931-041X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8253
dc.description.abstractEnBACKGROUND: Hemolytic uremic syndrome (HUS) has been associated with a number of infectious agents. We report here the case of an infant with severe Bordetella pertussis infection who developed HUS. CASE DIAGNOSIS/TREATMENT: A 2-month-old preterm male was admitted for severe Bordetella pertussis infection. Symptoms leading to a diagnosis of hemolytic uremic syndrome (HUS) rapidly appeared: hemolytic anemia, thrombocytopenia, and acute kidney injury. He was treated with 25 days of peritoneal dialysis and received complement-targeting therapy with eculizumab (five injections over 2 months), in addition to blood transfusions, antibiotics, and respiratory support. The outcome was favorable. The genetic workup found a complement factor H gene variant which has been associated with atypical HUS. This variant was located in the C3b-binding site and functional tests revealed that it perturbed the regulatory activity of factor H. CONCLUSION: This case suggests that pertussis is a strong trigger of HUS and that complement investigations are necessary to guide treatment and understand the pathophysiology.
dc.language.isoENen_US
dc.subject.enLEHA
dc.titleDu médicament psychoactif à l'addictovigilance dans le Code de la sante publique en France (1990-2017)
dc.title.enHemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H
dc.title.alternativePediatr Nephrolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00467-018-4174-1en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30560448en_US
bordeaux.journalPediatric Nephrologyen_US
bordeaux.page533-537en_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209861
hal.version1
hal.date.transferred2021-04-27T13:02:49Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.title=Du%20m%C3%A9dicament%20psychoactif%20%C3%A0%20l'addictovigilance%20dans%20le%20Code%20de%20la%20sante%20publique%20en%20France%20(1990-2017)&rft.atitle=Du%20m%C3%A9dicament%20psychoactif%20%C3%A0%20l'addictovigilance%20dans%20le%20Code%20de%20la%20sante%20publique%20en%20France%20(1990-2017)&rft.jtitle=Pediatric%20Nephrology&rft.date=2019-03&rft.volume=34&rft.issue=3&rft.spage=533-537&rft.epage=533-537&rft.eissn=1432-198X%20(Electronic)%200931-041X%20(Linking)&rft.issn=1432-198X%20(Electronic)%200931-041X%20(Linking)&rft.au=MADDEN,%20I.&ROUMENINA,%20L.%20T.&LANGLOIS-MEURINNE,%20H.&GUICHOUX,%20J.&LLANAS,%20B.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée